Study findings demonstrate a statistically significant reduction in bacteria on implant surfaces processed with Tyber Medical's BioTy™ Modified Surface Treatment. Specifically, use of the treatment supported a reduction of Staphylococcus Aureus, Pseudomonas Aeruginosa and antibiotic-resistant E. Coli without use of pharmacological agents.
Source: Tyber Medical, LLC
The company cites an estimated $9.8BB spent annually to treat hospital-acquired infections, of which surgical site infections (SSIs) represent the largest source of infection. Presently, SSIs require rigorous treatment with antibiotics and, in some instances, multiple surgical procedures. As health insurers transition to bundled payments, hospital systems will have to absorb infection-related costs, such as hardware removal and follow-up.
BioTy can be applied to titanium, stainless steel, cobalt chrome and PEEK. Tyber Medical is exploring multiple commercialization strategies for its first product incorporating the technology, for which it acquired an exclusive licensing agreement in mid-2015.